MSC-EV for Wound Treatment

About Phoenestra

Phoenestra is a Vienna-based biotech advancing a pipeline of stem cell-derived extracellular vesicle (EV) therapeutics through its GMP-aligned EVscale™ manufacturing platform. The company's lead program is in pre-clinical development for diabetic wound treatment, with other undisclosed regenerative medicine indications under investigation. Operating as a private entity, Phoenestra combines therapeutic development with R&D and upcoming GMP services, positioning itself at the intersection of advanced bioprocessing and regenerative medicine.

Therapeutic Areas

Other Diabetic Wound Healing Drugs